{"ticker": {"uuid": "fbffdb96-6605-4c75-a92b-ecbfdce86d82", "symbol": "UTHR", "name": "United Therapeutics Corporation", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "Is United Therapeutics a \"Quant King\" Favorite for a Reason", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQbGhHWFo5NzJPcjlVSFF2Z2xTcHlkV3dIdm1kcWFKYUJSTHFHeTkteUJjZkhiQXlSejFRNVpYTmhaR2wzNld3VFN6OTcxc1RBYUkzcjN5VTdiYjlGM2RLNTFjMnNkUVNsYldCcFpTRm9wUmxRSFI5MEZKQ0FteGZhRzhnWE9Xb05lYy1lTWdqS2tNVjRGVGFV?oc=5", "source_name": "Kavout | AI", "published_at": "2026-07-16T00:14:46+00:00", "published_display": "16 Jul 2026 00:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics(UTHR.US) Officer Sells US$5.09 Million in Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE1FdXQtOXZiRTRXcWZ4ZEExZnVaeUYxVXNQNWw4OWRaRzVrNURhRlk0bFBXRGdYSHljUGFIUHNjX0l0cnFjY0FnY3p1emZSZ3pfNm05QW5qdw?oc=5", "source_name": "Moomoo", "published_at": "2026-07-14T21:32:40+00:00", "published_display": "14 Jul 2026 21:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics CEO Rothblatt sells $5.09m in company stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQTHFXVF9TakJDX3U2cHVVYWs5NklMYzFralJwdDRERElQN0x0QkVHalJiSkhoRmZTTGxsRzNER0xaMjRSTUJwQWJpQVNMYVc4VlFxLXBqR3pZdjNETHU1MV8tVnVKcDVuY01RNFktaVh4QVhlcnEtdjllVThoX1ZxLXVaelBFRXpFVFNvU1h2MUtrLV9KeWZrZm9NOUxKSjlCbHE0Y0NMVDk2VnQzUUU1TUVPTEx6dXdtSl9BR0ZnWTZvTnpD?oc=5", "source_name": "Investing.com", "published_at": "2026-07-14T21:10:52+00:00", "published_display": "14 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics Insider Sold Shares Worth $5,091,949, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/united-therapeutics-insider-sold-shares-203616497.html", "source_name": "MT Newswires", "published_at": "2026-07-14T20:36:16+00:00", "published_display": "14 Jul 2026 20:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics(UTHR.US) Officer Sells US$5.17 Million in Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOZjQ4YkMzVUh0ekVpYV9wZmJmamV1RXVWalNyR0ViZWRCcEtZSlBEUGQ5X0JycFg5amxnSTdEYmdZYV9oRFJ4UzNIbDJrRndxX2JpaXZtYnl6dHQxQXdneVV5UVllenE4eWhWOWVqTlcxdzhBMVpPamVJUGRQeE1nbWd3NzdocEVyTHVuSm9UblJmNWNCLTBjbTIxVTZyaWJUNVdB?oc=5", "source_name": "Moomoo", "published_at": "2026-07-14T08:28:02+00:00", "published_display": "14 Jul 2026 08:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics Insider Sold Shares Worth $5,173,660, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/united-therapeutics-insider-sold-shares-204051676.html", "source_name": "MT Newswires", "published_at": "2026-07-13T20:40:51+00:00", "published_display": "13 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 United Therapeutics Corporation For: 13 July By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for United Therapeutics Corporation related to July 13th. Form 4 filings typically disclose changes in beneficial ownership of a company's securities by officers, directors, or significant shareholders. The article is bri", "url": "https://ca.investing.com/news/stock-market-news/form-4-united-therapeutics-corporation-for-13-july-93CH-4731863", "source_name": "Investing.com Canada", "published_at": "2026-07-13T21:10:42", "published_display": "13 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] UNITED THERAPEUTICS Corp Insider Trading Activity", "summary": "Martine A. Rothblatt, Chairperson & CEO of UNITED THERAPEUTICS Corp, reported insider trading activity on July 10, 2026. She exercised 9,500 stock options at $135.42 per share and subsequently sold 9,500 shares of Common Stock in multiple open-market transactions, ranging from $5", "url": "https://www.stocktitan.net/sec-filings/UTHR/form-4-united-therapeutics-corp-insider-trading-activity-135a76dceaf1.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:41:30", "published_display": "13 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics (UTHR) Stock Looks Cheap On Fair Value Despite Strong Returns", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNV0tvY3dXMHN2dG5RQkZlcUxWRkY1cmU5amJBUjZFNndKTkIyREVvWnhMaHl6VmRUb0hwQzRJMXZ0a2FzaWt1UFRGY1AzV0ZJT2NSX2JHdFR4WGYzYzNYYnI5bjA1RVUyNzR2N1N1cjFFTnV0UV9JV1FPMng3djZ1N0pOc1J4Q3NrZzF0ZEtrUDdNQTR5WWZPWmxPN3VUdE1kTlhN?oc=5", "source_name": "Market source", "published_at": "2026-07-12T12:07:56+00:00", "published_display": "12 Jul 2026 12:07", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics (UTHR) Following FDA Approval Is The Stock Fully Valued", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQNVlHblhSR09CYThPWW1feVhIUnppUnNsdmk4Y1hmV0VYR1lMblI4NmRmbFI0eFFpSW1la21tX3VMUWlWVkc5cFpFOVlzeko3TW4yZEwzSEVlSlE5MmtEMC1EUS1vdmtEOGVQX2w4LVc0Tk9zcDJybGtxNnBKdlNMN2o0SUpSVHFPVHEtRl9zd0NZcTFyaTNub2VxU3lIb01HRHA1d0RR?oc=5", "source_name": "Market source", "published_at": "2026-07-11T19:08:30+00:00", "published_display": "11 Jul 2026 19:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 UNITED THERAPEUTICS CORPORATION For: 10 July By Investing.com", "summary": "This article announces the filing of Form 144 for UNITED THERAPEUTICS CORPORATION on July 10. Such filings typically report insider intent to sell restricted stock. The content provides basic information about the filing without further details on the transaction itself.", "url": "https://ca.investing.com/news/stock-market-news/form-144-united-therapeutics-corporation-for-10-july-93CH-4729708", "source_name": "Investing.com Canada", "published_at": "2026-07-10T20:40:38", "published_display": "10 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 United Therapeutics Corporation For: 10 July By Investing.com", "summary": "This article provides details of a Form 4 filing for United Therapeutics Corporation on July 10. Form 4 filings are regulatory documents indicating changes in beneficial ownership of securities by company insiders. The publication comes from Investing.com.", "url": "https://ca.investing.com/news/stock-market-news/form-4-united-therapeutics-corporation-for-10-july-93CH-4729718", "source_name": "Investing.com Canada", "published_at": "2026-07-10T20:40:38", "published_display": "10 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics director Jan Malcolm sells $178,941 in stock By Investing.com", "summary": "United Therapeutics Corp director Jan Malcolm sold 325 shares of the company's stock for $178,941 on July 10, 2026, following the vesting of restricted stock units. The transaction was executed under a pre-arranged 10b5-1 plan established in September 2025. United Therapeutics ha", "url": "https://ca.investing.com/news/stock-market-news/united-therapeutics-director-jan-malcolm-sells-178941-in-stock-93CH-4729698", "source_name": "Investing.com Canada", "published_at": "2026-07-10T20:39:45", "published_display": "10 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BofA Securities Adjusts United Therapeutics Price Target to $613 From $620", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/bofa-securities-adjusts-united-therapeutics-142336574.html", "source_name": "MT Newswires", "published_at": "2026-07-10T14:23:36+00:00", "published_display": "10 Jul 2026 14:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics Insider Sold Shares Worth $5,235,756, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/united-therapeutics-insider-sold-shares-073918803.html", "source_name": "MT Newswires", "published_at": "2026-07-10T07:39:18+00:00", "published_display": "10 Jul 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics(UTHR.US) Officer Sells US$5.24 Million in Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNaG5vcDAyVDhDaEs5THIxai04LWhxV0hvb1ZrVTYtT1RRR2swNDFxc2dUR1hPSEhWWjVCY29COExKenFkMmRxb2V4Mk5kWlVxdG5GcTJqSy1Gam1oaGJyZkZad1FXLVVJUTZoZ2VMT3lMbkFYWG9ia2hEZ3VJWV9Salk4UXFsc19hYmxCY1YzbjVrS0p0aDZ5UGRFdmttQlVCOG40?oc=5", "source_name": "Moomoo", "published_at": "2026-07-10T06:52:07+00:00", "published_display": "10 Jul 2026 06:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics director Jan Malcolm sells $178,941 in stock", "summary": "United Therapeutics director Jan Malcolm sold 325 shares of company stock worth $178,941 on July 10, 2026, following the vesting of restricted stock units. The sale was executed under a pre-arranged 10b5-1 plan. Despite the sale, the company maintains a \"GREAT\" financial health s", "url": "https://www.investing.com/news/insider-trading-news/united-therapeutics-director-jan-malcolm-sells-178941-in-stock-93CH-4786753", "source_name": "Investing.com", "published_at": "2026-07-10T04:07:00", "published_display": "10 Jul 2026 04:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics CEO Martine Rothblatt sells $5.2m shares By Investing.com", "summary": "Martine A. Rothblatt, CEO of United Therapeutics Corp, sold approximately $5.24 million worth of common stock on July 9, 2026. This transaction followed the exercise of stock options and was executed under a pre-arranged 10b5-1 trading plan. The article also mentions the company'", "url": "https://ng.investing.com/news/stock-market-news/united-therapeutics-ceo-martine-rothblatt-sells-52m-shares-93CH-2594149", "source_name": "Investing.com Nigeria", "published_at": "2026-07-10T01:11:17", "published_display": "10 Jul 2026 01:11", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Martine Rothblatt, United Therapeutics chairperson & CEO, sells $5.25m By Investing.com", "summary": "Martine Rothblatt, Chairperson and CEO of United Therapeutics Corp, recently sold over $5.25 million in company stock after exercising options valued at $1.28 million. These transactions, executed under a pre-arranged 10b5-1 trading plan, highlight significant insider activity fo", "url": "https://ca.investing.com/news/stock-market-news/martine-rothblatt-united-therapeutics-chairperson--ceo-sells-525m-93CH-4728111", "source_name": "Investing.com Canada", "published_at": "2026-07-09T21:05:25", "published_display": "09 Jul 2026 21:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics Stock Rises 14% YTD: Here's What You Need to Know", "summary": "United Therapeutics (UTHR) stock has risen 14% year-to-date due to clinical breakthroughs and improved long-term growth visibility. The company is expanding its nebulized Tyvaso into larger pulmonary fibrosis markets and has successful late-stage pipeline candidates like ralinepa", "url": "https://www.tradingview.com/news/zacks:fde950df9094b:0-united-therapeutics-stock-rises-14-ytd-here-s-what-you-need-to-know/", "source_name": "TradingView", "published_at": "2026-07-09T18:05:24", "published_display": "09 Jul 2026 18:05", "sentiment": "positive", "sentiment_pct": 80, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics (UTHR) Q1 2026 earnings summary", "summary": "United Therapeutics (UTHR) reported Q1 2026 revenues of $781.5\u2013$782 million, a 2% year-over-year decrease, with net income falling 15% to $274.9 million. Despite overall revenue decline, Orenitram sales reached a record high, and Tyvaso DPI sales increased by 9%. The company anti", "url": "https://quartr.com/events/united-therapeutics-corporation-uthr-q1-2026_oqFyK9mJ", "source_name": "Quartr", "published_at": "2026-07-09T06:40:19", "published_display": "09 Jul 2026 06:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics (UTHR) Proxy filing Summary", "summary": "United Therapeutics (UTHR) has released its proxy filing summary for the upcoming annual meeting on June 26, 2026. Shareholders will vote on director elections, executive compensation, a new stock incentive plan, and auditor ratification. The company reported 11% revenue growth a", "url": "https://quartr.com/events/united-therapeutics-corporation-uthr-proxy-filing_oqFyKQ8n", "source_name": "Quartr", "published_at": "2026-07-09T05:05:24", "published_display": "09 Jul 2026 05:05", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics (UTHR) Q2 2025 earnings summary", "summary": "United Therapeutics (UTHR) reported record total revenue of $799 million for Q2 2025, a 12% year-over-year increase, marking 12 consecutive quarters of double-digit growth driven by products like Tyvaso DPI, Nebulized Tyvaso, Orenitram, and Unituxin. The company's board authorize", "url": "https://quartr.com/events/united-therapeutics-corporation-uthr-q2-2025_oqFyyegA", "source_name": "Quartr", "published_at": "2026-07-09T04:05:25", "published_display": "09 Jul 2026 04:05", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics (UTHR) Study result Summary", "summary": "United Therapeutics (UTHR) announced the results of its Phase III ADVANCE OUTCOMES study for ralinepag in patients with Pulmonary Arterial Hypertension (PAH). The study showed that ralinepag significantly reduced the risk of clinical worsening events by 55% compared to placebo, w", "url": "https://quartr.com/events/united-therapeutics-corporation-uthr-study-result_oqFyKelV", "source_name": "Quartr", "published_at": "2026-07-09T03:40:20", "published_display": "09 Jul 2026 03:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 United Therapeutics Corporation For: 8 July By Investing.com", "summary": "This article announces the filing of Form 4 for United Therapeutics Corporation on July 8th. Form 4 reports changes in beneficial ownership of company stock by insiders. The article provides no further details beyond this announcement.", "url": "https://ca.investing.com/news/stock-market-news/form-4-united-therapeutics-corporation-for-8-july-93CH-4726041", "source_name": "Investing.com Canada", "published_at": "2026-07-08T20:40:20", "published_display": "08 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics CEO Martine Rothblatt sells $5.3m company stock By Investing.com", "summary": "United Therapeutics CEO Martine Rothblatt sold 9,500 shares of the company's common stock for approximately $5.31 million after exercising stock options worth $1.29 million. These transactions were conducted under a pre-arranged 10b5-1 trading plan. The company's shares have rise", "url": "https://ca.investing.com/news/stock-market-news/united-therapeutics-ceo-martine-rothblatt-sells-53m-company-stock-93CH-4726030", "source_name": "Investing.com Canada", "published_at": "2026-07-08T20:39:13", "published_display": "08 Jul 2026 20:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is United Therapeutics Corporation (UTHR) Stock a Long-Term Opportunity in Organ Transplant Innovation?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPQnBvRHNuZTFPRlNBYldwem5tRWpvN2pGWlRKXzcyMUVVLUVtXzZDSmRRVnRFSDFJd0FjMV9GTXE3M25tdjFxQ2d3b2prSFo2eVJvQk9nb1VGQ1c1clg5MlFWRjc5TzJGeTMxbHpSODlHQ2Z6S3dVdnlnTl9XM2ZBNWdCeTVoVmZwakVvTGxRQ2ZuY2h4VlV1d3Z3LUgzRnVKRkFfNzFB?oc=5", "source_name": "Market source", "published_at": "2026-07-08T14:50:14+00:00", "published_display": "08 Jul 2026 14:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics expands immune therapy pipeline with Thymmune", "summary": "United Therapeutics (UTHR) has acquired Thymmune Therapeutics for $140 million in cash and potential earn-out payments of up to $160 million. Thymmune specializes in preclinical regenerative thymic cell therapies aimed at restoring immune function and improving transplant outcome", "url": "https://biobuzz.io/news/united-therapeutics-expands-immune-therapy-pipeline-with-thymmune/", "source_name": "BioBuzz", "published_at": "2026-07-08T14:39:13", "published_display": "08 Jul 2026 14:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What United Therapeutics (UTHR)'s Centralized LungFX EVLP FDA Approval Means For Shareholders", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-08T04:51:59+00:00", "published_display": "08 Jul 2026 04:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics Corp (UTHR) Stock Up 3.0% but GF Value Says Overvalued -- GF Score: 88/100", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxNM0FTSkpGUHg3LVNHY0RXeTllTEVCeEc2RFRvaDZ3aVN0b2hnS3cwRGJKOFlLMmw4RFFsNnpOSVJHY2k4RmZYUnE3bWhoTU1BX2w1LURlTS13S1N5VUgxZTFmZC1FTzBmQVZmTFZ6TkFxbnFpdEx1cnh6NFFETGNQaFJwUWVFQjRLVWo4M3QzSDFjakNfek9ZR0wzdVZnWEs1bmxrb0VJdWNwMW9QYTVPNU1pcERXWnlnYXA3Z3NsVlpUekhaME9pQ1B0dThIZjlkMFE?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-07T22:33:28+00:00", "published_display": "07 Jul 2026 22:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics CEO Rothblatt sells $5.2m in company stock", "summary": "Martine A. Rothblatt, CEO of United Therapeutics Corp., sold approximately $5.2 million worth of company stock through a pre-arranged trading plan, following an 88% surge in share value over the past year. These sales occurred after she exercised stock options worth about $1.28 m", "url": "https://www.investing.com/news/insider-trading-news/united-therapeutics-ceo-rothblatt-sells-52m-in-company-stock-93CH-4779451", "source_name": "Investing.com", "published_at": "2026-07-07T14:10:16", "published_display": "07 Jul 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RTP drugmaker strikes $300M deal for Massachusetts company", "summary": "United Therapeutics, based in Research Triangle Park, has acquired Massachusetts-based Thymmune for $300 million. This acquisition marks a significant expansion for United Therapeutics into regenerative medicine and organ transplants. The deal was reported by Zac Ezzone of the Tr", "url": "https://www.bizjournals.com/triangle/news/2026/07/06/united-therapeutics-acquires-thymmune.html", "source_name": "The Business Journals", "published_at": "2026-07-06T22:39:13", "published_display": "06 Jul 2026 22:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics Corporation (UTHR) Stock Analysis: A Closer Look at Its 19.67% Potential Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxNZW42dnVCcnE0R2ViTXFsbzFPS0l1VldYb0hnVDY4RWpnSmNmczRONlNEOEVtTXQzTzY2Y1BKMnA2ZFl0VzZjV193S1dwYTJ0OXhoT0RIRERvR3cxemstSEc1Nk5RTXkzcHptVlZmWWtKb3BfVWhkV3BoaUJjbTR2c1ZSdnljb2hkb3A3M3RxaW5ubnNsOGV3cTR5WEdEWXE3aHhCbF9iMFl6anVzYTN6emhZWm5zb1dpN2dGNDE5YjR5Z09hSTJWbkpLSnVnWGpaOTJyRWRZMmc2Wi0zVFdn?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-06T09:21:47+00:00", "published_display": "06 Jul 2026 09:21", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics (UTHR) Following LungFX Approval Is It A Buying Opportunity Or Priced In", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind Stock Plummets After Partner United Therapeutics Unveils New \u2018Category Killer Product\u2019", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7gFBVV95cUxQX2cyYnVaVExIWG1QRjNUMVdkQ1Y2eW5VRzJ2WE13ckJXenVLV3F6ZFR4SEcyR2lsc2pveERra0ZxV3ZUUDZTNndrcXZ3aXFGenRmUkZacnM2THRPaTZ2dXdQR3k5ZDh6Q3dpUEV5cll0cUw3c1o2bTZmX2hvXzJkZEhaeDAxYV9id2hodTlQUUt2VWVtNzdMbzhKSFJTd3JXSVNwVGVRZWYxR0Q3aTJwT2ZrYThYU1ZvV2dIRlgzaXhGSzk5dndObW0wclU5QW9zQW5CeDhqQ0JuSm16Wlk5QlZ6aVdVdW0zNVh5MTJn?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-03T03:21:09+00:00", "published_display": "03 Jul 2026 03:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: United Therapeutics Corporation Acquires Thymmune Therapeutics", "summary": "United Therapeutics Corporation has announced the acquisition of Thymmune Therapeutics. The terms of the acquisition, including the financial details and strategic implications for both companies, are expected to be elaborated upon in the full press release. This move signifies U", "url": "https://www.moomoo.com/news/post/72393890/press-release-united-therapeutics-corporation-acquires-thymmune-therapeutics", "source_name": "Moomoo", "published_at": "2026-07-02T22:39:13", "published_display": "02 Jul 2026 22:39", "sentiment": "positive", "sentiment_pct": 68, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics buys Massachusetts biotech Thymmune Therapeutics for $140M", "summary": "United Therapeutics has acquired Thymmune Therapeutics for $140 million, a move that aligns with United Therapeutics' mission to enhance organ health and transplants. The acquisition occurred shortly after United Therapeutics received FDA premarket approval for a lung transplant ", "url": "https://www.bizjournals.com/washington/news/2026/07/02/united-therapeutics-thymmune-acquisition.html", "source_name": "The Business Journals", "published_at": "2026-07-02T20:11:39", "published_display": "02 Jul 2026 20:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Thymmune Therapeutics acquired by Maryland biotech for $140M", "summary": "Thymmune Therapeutics has been acquired by United Therapeutics for $140 million. This acquisition, which closed on Thursday, integrates Thymmune's thymus cell therapy platform with United Therapeutics' focus on lung disease treatments and pig-to-human transplant research. The dea", "url": "https://www.bizjournals.com/boston/news/2026/07/02/thymmune-acquisition-united-therapeutics.html", "source_name": "The Business Journals", "published_at": "2026-07-02T19:35:39", "published_display": "02 Jul 2026 19:35", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics acquires Thymmune for $140 million", "summary": "United Therapeutics (NASDAQ:UTHR) has acquired Thymmune Therapeutics for $140 million in cash, with potential additional milestone payments of up to $160 million. Thymmune specializes in preclinical regenerative thymic cell therapies for immune-related diseases, including THY-100", "url": "https://grafa.com/en/news/united-states/united-therapeutics-acquires-thymmune-140-million", "source_name": "grafa.com", "published_at": "2026-07-02T14:11:39", "published_display": "02 Jul 2026 14:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics buys Thymmune, adding thymus cell therapy platform", "summary": "United Therapeutics (NASDAQ: UTHR) has acquired Thymmune Therapeutics for $140 million in cash, with potential earn-out payments of up to $160 million. Thymmune specializes in scalable, regenerative thymic cell therapies derived from induced pluripotent stem cells (iPSC), aimed a", "url": "https://www.stocktitan.net/news/UTHR/united-therapeutics-corporation-acquires-thymmune-rcxz36hclcar.html", "source_name": "Stock Titan", "published_at": "2026-07-02T10:11:39", "published_display": "02 Jul 2026 10:11", "sentiment": "positive", "sentiment_pct": 73, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics Corporation acquired Thymmune Therapeutics, Inc. for $300 million.", "summary": "United Therapeutics Corporation (NasdaqGS:UTHR) has acquired Thymmune Therapeutics, Inc. for a total consideration of $300 million. The acquisition includes an upfront payment of $140 million in cash, with an additional potential $160 million in earn-out payments tied to clinical", "url": "https://www.marketscreener.com/news/united-therapeutics-corporation-acquired-thymmune-therapeutics-inc-for-300-million-ce7f5fd3d08cf327", "source_name": "www.marketscreener.com", "published_at": "2026-07-02T08:40:00", "published_display": "02 Jul 2026 08:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics chairperson & CEO Rothblatt sells $5.18m stock By Investing.com", "summary": "Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, sold 9,500 shares of the company\u2019s common stock for approximately $5.18 million. This transaction followed the exercise of stock options and was conducted under a pre-arranged 10b5-1 trading plan. Despite the in", "url": "https://ng.investing.com/news/stock-market-news/united-therapeutics-chairperson--ceo-rothblatt-sells-518m-stock-93CH-2581009", "source_name": "Investing.com Nigeria", "published_at": "2026-07-01T20:11:08", "published_display": "01 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Oliver Patch Project Announces United Therapeutics Corporation Named Visionary/Presenting Sponsor of National Patch Day 2026", "summary": "The Oliver Patch Project has announced that United Therapeutics Corporation will be the Visionary/Presenting Sponsor for National Patch Day 2026. This initiative aims to spread hope and encouragement to children, teens, and young adults nationwide who are facing cancer, serious i", "url": "https://www.prnewswire.com/news-releases/the-oliver-patch-project-announces-united-therapeutics-corporation-named-visionarypresenting-sponsor-of-national-patch-day-2026-302815896.html", "source_name": "PR Newswire", "published_at": "2026-07-01T13:39:19", "published_display": "01 Jul 2026 13:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics Corporation Acquires Thymmune Therapeutics", "summary": "United Therapeutics Corporation has acquired Thymmune Therapeutics for $140 million in cash, plus potential earn-out payments of up to $160 million. Thymmune specializes in scalable, regenerative thymic cell therapies for conditions like post-transplant organ tolerance, immunodef", "url": "https://ir.unither.com/press-releases/2026/07-02-2026-113022825", "source_name": "United Therapeutics Investor Relations", "published_at": "2026-07-01T00:12:07", "published_display": "01 Jul 2026 00:12", "sentiment": "positive", "sentiment_pct": 71, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics Insider Sold Shares Worth $5,167,734, According to a Recent SEC Filing", "summary": "An insider at United Therapeutics Corporation recently sold shares totaling $5,167,734, as disclosed in a recent SEC filing. The article, however, is reserved for members only, requiring registration to access the full details of the transaction. United Therapeutics develops and ", "url": "https://www.marketscreener.com/news/united-therapeutics-insider-sold-shares-worth-5-167-734-according-to-a-recent-sec-filing-ce7f5fdfdd80f627", "source_name": "www.marketscreener.com", "published_at": "2026-06-30T19:39:19", "published_display": "30 Jun 2026 19:39", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Approves United Therapeutics\u2019 LungFX For Centralized Lung Perfusion, On A Narrow Indication", "summary": "The FDA has approved United Therapeutics' LungFX for centralized lung perfusion. The approval is specifically for a narrow indication, highlighting the targeted application of this medical device. This development is significant for the field of respiratory medicine.", "url": "https://insights.citeline.com/medtech-insight/policy-and-regulation/approvals/fda-approves-united-therapeutics-lungfx-for-centralized-lung-perfusion-on-a-narrow-indication-XXUEG4MZGJCR7PJGIEBHR3BPXM/", "source_name": "Medtech Insight", "published_at": "2026-06-30T13:09:45", "published_display": "30 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 76, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA approves United Therapeutics' LungFX to assess donor lungs", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNVVdaX0MtdEFZODVmaXU5UDVLR0pOeFBiaFVnWmtQeWg3WF9MRE1SemVqNkppTVBIYmlhem83VHA3dUQxMWY5VmpCN0EtRnhvS0YyZUtxeS1EdVNKVE4xYzdFY204XzlITnBzdTg4V2o5eVkxSlk0b2RIckpybnNkYWllVk4xbkpJd0d4SzdyejhUZ1JjRDZOd1NLM2Z0RXF6WmlycENyME5MclU0WWdlWjlzWXFHLVM3MjNTSkJB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics | UTHR Stock Price, Company Overview & News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiY0FVX3lxTFBnckpMRjBiNmc0aHZwc2ZxS1VoNUdPSGdiUjRiQl9VTEt3RWNlNTVXLVVuU0lCMDJHNEYwSEt2TG52VWJDMWxYbklPbFRJUHhjcUVHVHVRWU5iaXRLRHA5Ukt4cw?oc=5", "source_name": "Forbes", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics EVP Mahon sells $4.5m in company stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNekFJWUNvUVhZQS1kSXFWM0M2cDVUdFU3SkNGSlNRQ3VlWVlSc1VacGJUcXJLLVNSckNVaTI5Z0lKSnVLS1BjMnh6UWx3dUtLY2lwd1dXSHpyX2pBendCUWp0bDRZYlloRFFnaU1Pa3lJSkY1NkY0c0NhWjRZam5kMzRUckwzQmJ3bTBoRlN1bVZuS25qRU5uNHN4Umw5VXY0eC0tSDVOakJsbFZ4Q2FLeWV2YkNhMVdPMG80UjJ3?oc=5", "source_name": "Investing.com", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At United Therapeutics (UTHR) Valuation After Strong Long Term Shareholder Returns", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQRWEzdmN3d05USF9aelk3eHV6SHAwTTVzZVdiRUhZTmJjbWNGVk9OSl9QTnotd2pfT3RxZktfZVVHaFU0Q3htZjFScjRrdS1NdXNFYVk5NWYyZjkwZ0ZpM25YZnJ3R2pWbUctT3pjUUdwbEM3bFhmbWR1UldvWEpnanlmVEl4U1JQbHA0LXZya2VkZHdJUDRMdVIwcW42QTM3RlFxSXYyMA?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is United Therapeutics (UTHR) Down 3.8% Since Last Earnings Report?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQbUtpbjhyZm9DWjNrLVFrQXJSLW9UdHVHaWxSSmtSSWxDZGtfUHlnRVFSOXJIY2U4aEZDQlhUS29TZGZBZFZ3TmR0OURrV281OFh1ZWhxeHd4OTIzZ0pMYXVKRld6bV84NVRYQlRCZUFzZ3ZKd0dqVTdpX0pIRVVYckEyeEx6WUpQRmVuaEV5SUttZmRUMDVNTlYtamwwVE0?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Story Around United Therapeutics (UTHR) Is Shifting On Trials Pricing And Valuation", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQU2tGREs5ZzZNNWxmQ3VpME1rZmFWYVB6N01ENlVVelNSamFwcThZRVJZQVF6dXpVQWE5V2lBeGQxMGkxQ2EtVlg2YldkTWV4RjM3M1o0UGFTU3VmM19SakUteFZHUHdNVUxKM2RCYkIwNTNndVBWTnc5QUh2UnFuNnd1eUUtc3pDVWt5OUhIMlFyM09BOVBnZjhta0lJYW9QSW5QVQ?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics (UTHR): Company Profile, Stock Price, News, Rankings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTFBrNTlRY05sd1JFMlMxeTNmMzhvODN0XzRVVHlEUXJyUDZRWF8tRnhUQi1xdHVYYndZR0FfLWVoLXlZXzB0RngzNkk0MUpGNzhTNkd0V0NIRXFiQThR?oc=5", "source_name": "Fortune", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Insider Has Just Sold Shares In United Therapeutics", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics chairperson & CEO Rothblatt sells $5.5m in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOMmdaSXNiSlZ0ZDIwWEl6aE9mdE5xQ3JZd2l0RFo1VXhVeDlLVnYxdzFHak9MUnpOcFNGRkc0WE96VHBrQ1hzeWpaYTFqNlpIQzdxRUVqa3RoVmRBbV9tU0RTOWJia1BsMjRmYmJGSFo5NVMyaDlPS0xaTWNKcEQwbmdueTQ4NDhPeFQ4M0RxZVVNS2dnNUZpWWtSU19UbkFtbFJzcE5ueEV6MU1ORzBPZ25aYjVrcUI1XzQtZjVTM3JVbGVxX2hESGpR?oc=5", "source_name": "Investing.com", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider United Therapeutics (UTHR) After Its 94% One Year Surge?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind stock surges on United Therapeutics partnership deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQWEdUSkFDa3RRbWZYc3ZTelJ5dk8yYVhkM0ZSV0VQNnhheWsyVEl5eS1SUDhzMXg5dlAxZVJPLUk4Z0c2WDlRdnFON2hkM19rSTl3OTJKczFhb2Q1WVpIS21Pb0gxVk1PVUZaZXNSODkxT2cxeDEzTGZxN09YcXhXWE13VGtWdFppbk5UcjNCUlZxYktFUThCV3lVNlliN1M0X3hOX3NFbjNVVW1rZVZXbmFSWW9ETVJ4c3hRNk5sVDI?oc=5", "source_name": "Investing.com", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics (NASDAQ:UTHR) Reports Sales Below Analyst Estimates In Q1 CY2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxPMHZzemJjSl95blhMbTRZTVg1ZkxzQWFzRG5QcTNVOE9uMTVOY01MRVFRNEppank2V1YtNzZ1RVhIT2E5VUw1blJ1RHl1QnAtUGJ5VFdJNWtGWjJ0cTFLbk1vaWZ6TXFsNkJLWlRDUWplWkppSUhRTDlZOHlIeDBITzZaWjhEckpVRVBQdUlVVlhrLXRXcGxMOFB3WTNaSkVPNHZHckhUVjlHOWVMVUtKQXVkdDRHOExUZjgtSTFUOTdiOVN5TDhwY1dPbzM3dzJPOHdNWm1nZGhFNlBGNDMxbUYwbw?oc=5", "source_name": "StockStory", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "3 Reasons Investors Love United Therapeutics (UTHR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPQjdnZWhXQzBjYWZyNXpWRFBYUDlzdFZBZnIxZ0M0eVVCQjBrcWpCeHcyd0JsbC1Dazg0XzZIT0drZWdEQkwxM05BdGlhTUdxOVcwRkpUZmZJNXZtaGZuQkVsTThOZTFPTmFhMU9DVExEeF9ETmZLX1dGQ1ZTdVA1UW5vbm5Yd3NSQUNJV0x3bXcwcW5qTHREckczQmFzS214NF85VlBMWWJFYmtTcmdORGF5VQ?oc=5", "source_name": "StockStory", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider United Therapeutics (UTHR) After Its 92% One Year Surge?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPTl91YVNfU2Rzbk9fUGl0c1A5ZXVDNjRxdFRvSG5iM2hnUUVhc1lRREEzVmdWdUtKWXByWDJ4VDROY1ZvVUhnTkdQUGVKSDZoWktFTXJqTmZVeDNxSkFBa0VCVlQ4YzU4NUpFRGhGdEZSTFBZYU5EVEI3SDhxRzBib2JaOWd0a2ViWVdYTF9JQ2otMEw5Mlg3UzJvNWswYUQ1N3FhdQ?oc=5", "source_name": "Market source", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Is United Therapeutics a \"Quant King\" Favorite for a Reason", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQbGhHWFo5NzJPcjlVSFF2Z2xTcHlkV3dIdm1kcWFKYUJSTHFHeTkteUJjZkhiQXlSejFRNVpYTmhaR2wzNld3VFN6OTcxc1RBYUkzcjN5VTdiYjlGM2RLNTFjMnNkUVNsYldCcFpTRm9wUmxRSFI5MEZKQ0FteGZhRzhnWE9Xb05lYy1lTWdqS2tNVjRGVGFV?oc=5", "source_name": "Kavout | AI", "published_at": "2026-07-16T00:14:46+00:00", "published_display": "16 Jul 2026 00:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics(UTHR.US) Officer Sells US$5.09 Million in Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE1FdXQtOXZiRTRXcWZ4ZEExZnVaeUYxVXNQNWw4OWRaRzVrNURhRlk0bFBXRGdYSHljUGFIUHNjX0l0cnFjY0FnY3p1emZSZ3pfNm05QW5qdw?oc=5", "source_name": "Moomoo", "published_at": "2026-07-14T21:32:40+00:00", "published_display": "14 Jul 2026 21:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics CEO Rothblatt sells $5.09m in company stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQTHFXVF9TakJDX3U2cHVVYWs5NklMYzFralJwdDRERElQN0x0QkVHalJiSkhoRmZTTGxsRzNER0xaMjRSTUJwQWJpQVNMYVc4VlFxLXBqR3pZdjNETHU1MV8tVnVKcDVuY01RNFktaVh4QVhlcnEtdjllVThoX1ZxLXVaelBFRXpFVFNvU1h2MUtrLV9KeWZrZm9NOUxKSjlCbHE0Y0NMVDk2VnQzUUU1TUVPTEx6dXdtSl9BR0ZnWTZvTnpD?oc=5", "source_name": "Investing.com", "published_at": "2026-07-14T21:10:52+00:00", "published_display": "14 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics Insider Sold Shares Worth $5,091,949, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/united-therapeutics-insider-sold-shares-203616497.html", "source_name": "MT Newswires", "published_at": "2026-07-14T20:36:16+00:00", "published_display": "14 Jul 2026 20:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics(UTHR.US) Officer Sells US$5.17 Million in Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOZjQ4YkMzVUh0ekVpYV9wZmJmamV1RXVWalNyR0ViZWRCcEtZSlBEUGQ5X0JycFg5amxnSTdEYmdZYV9oRFJ4UzNIbDJrRndxX2JpaXZtYnl6dHQxQXdneVV5UVllenE4eWhWOWVqTlcxdzhBMVpPamVJUGRQeE1nbWd3NzdocEVyTHVuSm9UblJmNWNCLTBjbTIxVTZyaWJUNVdB?oc=5", "source_name": "Moomoo", "published_at": "2026-07-14T08:28:02+00:00", "published_display": "14 Jul 2026 08:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics Insider Sold Shares Worth $5,173,660, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/united-therapeutics-insider-sold-shares-204051676.html", "source_name": "MT Newswires", "published_at": "2026-07-13T20:40:51+00:00", "published_display": "13 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 United Therapeutics Corporation For: 13 July By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for United Therapeutics Corporation related to July 13th. Form 4 filings typically disclose changes in beneficial ownership of a company's securities by officers, directors, or significant shareholders. The article is bri", "url": "https://ca.investing.com/news/stock-market-news/form-4-united-therapeutics-corporation-for-13-july-93CH-4731863", "source_name": "Investing.com Canada", "published_at": "2026-07-13T21:10:42", "published_display": "13 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] UNITED THERAPEUTICS Corp Insider Trading Activity", "summary": "Martine A. Rothblatt, Chairperson & CEO of UNITED THERAPEUTICS Corp, reported insider trading activity on July 10, 2026. She exercised 9,500 stock options at $135.42 per share and subsequently sold 9,500 shares of Common Stock in multiple open-market transactions, ranging from $5", "url": "https://www.stocktitan.net/sec-filings/UTHR/form-4-united-therapeutics-corp-insider-trading-activity-135a76dceaf1.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:41:30", "published_display": "13 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics (UTHR) Stock Looks Cheap On Fair Value Despite Strong Returns", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNV0tvY3dXMHN2dG5RQkZlcUxWRkY1cmU5amJBUjZFNndKTkIyREVvWnhMaHl6VmRUb0hwQzRJMXZ0a2FzaWt1UFRGY1AzV0ZJT2NSX2JHdFR4WGYzYzNYYnI5bjA1RVUyNzR2N1N1cjFFTnV0UV9JV1FPMng3djZ1N0pOc1J4Q3NrZzF0ZEtrUDdNQTR5WWZPWmxPN3VUdE1kTlhN?oc=5", "source_name": "Market source", "published_at": "2026-07-12T12:07:56+00:00", "published_display": "12 Jul 2026 12:07", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics (UTHR) Following FDA Approval Is The Stock Fully Valued", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQNVlHblhSR09CYThPWW1feVhIUnppUnNsdmk4Y1hmV0VYR1lMblI4NmRmbFI0eFFpSW1la21tX3VMUWlWVkc5cFpFOVlzeko3TW4yZEwzSEVlSlE5MmtEMC1EUS1vdmtEOGVQX2w4LVc0Tk9zcDJybGtxNnBKdlNMN2o0SUpSVHFPVHEtRl9zd0NZcTFyaTNub2VxU3lIb01HRHA1d0RR?oc=5", "source_name": "Market source", "published_at": "2026-07-11T19:08:30+00:00", "published_display": "11 Jul 2026 19:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 UNITED THERAPEUTICS CORPORATION For: 10 July By Investing.com", "summary": "This article announces the filing of Form 144 for UNITED THERAPEUTICS CORPORATION on July 10. Such filings typically report insider intent to sell restricted stock. The content provides basic information about the filing without further details on the transaction itself.", "url": "https://ca.investing.com/news/stock-market-news/form-144-united-therapeutics-corporation-for-10-july-93CH-4729708", "source_name": "Investing.com Canada", "published_at": "2026-07-10T20:40:38", "published_display": "10 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 United Therapeutics Corporation For: 10 July By Investing.com", "summary": "This article provides details of a Form 4 filing for United Therapeutics Corporation on July 10. Form 4 filings are regulatory documents indicating changes in beneficial ownership of securities by company insiders. The publication comes from Investing.com.", "url": "https://ca.investing.com/news/stock-market-news/form-4-united-therapeutics-corporation-for-10-july-93CH-4729718", "source_name": "Investing.com Canada", "published_at": "2026-07-10T20:40:38", "published_display": "10 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics director Jan Malcolm sells $178,941 in stock By Investing.com", "summary": "United Therapeutics Corp director Jan Malcolm sold 325 shares of the company's stock for $178,941 on July 10, 2026, following the vesting of restricted stock units. The transaction was executed under a pre-arranged 10b5-1 plan established in September 2025. United Therapeutics ha", "url": "https://ca.investing.com/news/stock-market-news/united-therapeutics-director-jan-malcolm-sells-178941-in-stock-93CH-4729698", "source_name": "Investing.com Canada", "published_at": "2026-07-10T20:39:45", "published_display": "10 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BofA Securities Adjusts United Therapeutics Price Target to $613 From $620", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/bofa-securities-adjusts-united-therapeutics-142336574.html", "source_name": "MT Newswires", "published_at": "2026-07-10T14:23:36+00:00", "published_display": "10 Jul 2026 14:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics Insider Sold Shares Worth $5,235,756, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/united-therapeutics-insider-sold-shares-073918803.html", "source_name": "MT Newswires", "published_at": "2026-07-10T07:39:18+00:00", "published_display": "10 Jul 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics(UTHR.US) Officer Sells US$5.24 Million in Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNaG5vcDAyVDhDaEs5THIxai04LWhxV0hvb1ZrVTYtT1RRR2swNDFxc2dUR1hPSEhWWjVCY29COExKenFkMmRxb2V4Mk5kWlVxdG5GcTJqSy1Gam1oaGJyZkZad1FXLVVJUTZoZ2VMT3lMbkFYWG9ia2hEZ3VJWV9Salk4UXFsc19hYmxCY1YzbjVrS0p0aDZ5UGRFdmttQlVCOG40?oc=5", "source_name": "Moomoo", "published_at": "2026-07-10T06:52:07+00:00", "published_display": "10 Jul 2026 06:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics director Jan Malcolm sells $178,941 in stock", "summary": "United Therapeutics director Jan Malcolm sold 325 shares of company stock worth $178,941 on July 10, 2026, following the vesting of restricted stock units. The sale was executed under a pre-arranged 10b5-1 plan. Despite the sale, the company maintains a \"GREAT\" financial health s", "url": "https://www.investing.com/news/insider-trading-news/united-therapeutics-director-jan-malcolm-sells-178941-in-stock-93CH-4786753", "source_name": "Investing.com", "published_at": "2026-07-10T04:07:00", "published_display": "10 Jul 2026 04:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics CEO Martine Rothblatt sells $5.2m shares By Investing.com", "summary": "Martine A. Rothblatt, CEO of United Therapeutics Corp, sold approximately $5.24 million worth of common stock on July 9, 2026. This transaction followed the exercise of stock options and was executed under a pre-arranged 10b5-1 trading plan. The article also mentions the company'", "url": "https://ng.investing.com/news/stock-market-news/united-therapeutics-ceo-martine-rothblatt-sells-52m-shares-93CH-2594149", "source_name": "Investing.com Nigeria", "published_at": "2026-07-10T01:11:17", "published_display": "10 Jul 2026 01:11", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Martine Rothblatt, United Therapeutics chairperson & CEO, sells $5.25m By Investing.com", "summary": "Martine Rothblatt, Chairperson and CEO of United Therapeutics Corp, recently sold over $5.25 million in company stock after exercising options valued at $1.28 million. These transactions, executed under a pre-arranged 10b5-1 trading plan, highlight significant insider activity fo", "url": "https://ca.investing.com/news/stock-market-news/martine-rothblatt-united-therapeutics-chairperson--ceo-sells-525m-93CH-4728111", "source_name": "Investing.com Canada", "published_at": "2026-07-09T21:05:25", "published_display": "09 Jul 2026 21:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics Stock Rises 14% YTD: Here's What You Need to Know", "summary": "United Therapeutics (UTHR) stock has risen 14% year-to-date due to clinical breakthroughs and improved long-term growth visibility. The company is expanding its nebulized Tyvaso into larger pulmonary fibrosis markets and has successful late-stage pipeline candidates like ralinepa", "url": "https://www.tradingview.com/news/zacks:fde950df9094b:0-united-therapeutics-stock-rises-14-ytd-here-s-what-you-need-to-know/", "source_name": "TradingView", "published_at": "2026-07-09T18:05:24", "published_display": "09 Jul 2026 18:05", "sentiment": "positive", "sentiment_pct": 80, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics (UTHR) Q1 2026 earnings summary", "summary": "United Therapeutics (UTHR) reported Q1 2026 revenues of $781.5\u2013$782 million, a 2% year-over-year decrease, with net income falling 15% to $274.9 million. Despite overall revenue decline, Orenitram sales reached a record high, and Tyvaso DPI sales increased by 9%. The company anti", "url": "https://quartr.com/events/united-therapeutics-corporation-uthr-q1-2026_oqFyK9mJ", "source_name": "Quartr", "published_at": "2026-07-09T06:40:19", "published_display": "09 Jul 2026 06:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics (UTHR) Proxy filing Summary", "summary": "United Therapeutics (UTHR) has released its proxy filing summary for the upcoming annual meeting on June 26, 2026. Shareholders will vote on director elections, executive compensation, a new stock incentive plan, and auditor ratification. The company reported 11% revenue growth a", "url": "https://quartr.com/events/united-therapeutics-corporation-uthr-proxy-filing_oqFyKQ8n", "source_name": "Quartr", "published_at": "2026-07-09T05:05:24", "published_display": "09 Jul 2026 05:05", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics (UTHR) Q2 2025 earnings summary", "summary": "United Therapeutics (UTHR) reported record total revenue of $799 million for Q2 2025, a 12% year-over-year increase, marking 12 consecutive quarters of double-digit growth driven by products like Tyvaso DPI, Nebulized Tyvaso, Orenitram, and Unituxin. The company's board authorize", "url": "https://quartr.com/events/united-therapeutics-corporation-uthr-q2-2025_oqFyyegA", "source_name": "Quartr", "published_at": "2026-07-09T04:05:25", "published_display": "09 Jul 2026 04:05", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics (UTHR) Study result Summary", "summary": "United Therapeutics (UTHR) announced the results of its Phase III ADVANCE OUTCOMES study for ralinepag in patients with Pulmonary Arterial Hypertension (PAH). The study showed that ralinepag significantly reduced the risk of clinical worsening events by 55% compared to placebo, w", "url": "https://quartr.com/events/united-therapeutics-corporation-uthr-study-result_oqFyKelV", "source_name": "Quartr", "published_at": "2026-07-09T03:40:20", "published_display": "09 Jul 2026 03:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 United Therapeutics Corporation For: 8 July By Investing.com", "summary": "This article announces the filing of Form 4 for United Therapeutics Corporation on July 8th. Form 4 reports changes in beneficial ownership of company stock by insiders. The article provides no further details beyond this announcement.", "url": "https://ca.investing.com/news/stock-market-news/form-4-united-therapeutics-corporation-for-8-july-93CH-4726041", "source_name": "Investing.com Canada", "published_at": "2026-07-08T20:40:20", "published_display": "08 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics CEO Martine Rothblatt sells $5.3m company stock By Investing.com", "summary": "United Therapeutics CEO Martine Rothblatt sold 9,500 shares of the company's common stock for approximately $5.31 million after exercising stock options worth $1.29 million. These transactions were conducted under a pre-arranged 10b5-1 trading plan. The company's shares have rise", "url": "https://ca.investing.com/news/stock-market-news/united-therapeutics-ceo-martine-rothblatt-sells-53m-company-stock-93CH-4726030", "source_name": "Investing.com Canada", "published_at": "2026-07-08T20:39:13", "published_display": "08 Jul 2026 20:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is United Therapeutics Corporation (UTHR) Stock a Long-Term Opportunity in Organ Transplant Innovation?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPQnBvRHNuZTFPRlNBYldwem5tRWpvN2pGWlRKXzcyMUVVLUVtXzZDSmRRVnRFSDFJd0FjMV9GTXE3M25tdjFxQ2d3b2prSFo2eVJvQk9nb1VGQ1c1clg5MlFWRjc5TzJGeTMxbHpSODlHQ2Z6S3dVdnlnTl9XM2ZBNWdCeTVoVmZwakVvTGxRQ2ZuY2h4VlV1d3Z3LUgzRnVKRkFfNzFB?oc=5", "source_name": "Market source", "published_at": "2026-07-08T14:50:14+00:00", "published_display": "08 Jul 2026 14:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics expands immune therapy pipeline with Thymmune", "summary": "United Therapeutics (UTHR) has acquired Thymmune Therapeutics for $140 million in cash and potential earn-out payments of up to $160 million. Thymmune specializes in preclinical regenerative thymic cell therapies aimed at restoring immune function and improving transplant outcome", "url": "https://biobuzz.io/news/united-therapeutics-expands-immune-therapy-pipeline-with-thymmune/", "source_name": "BioBuzz", "published_at": "2026-07-08T14:39:13", "published_display": "08 Jul 2026 14:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What United Therapeutics (UTHR)'s Centralized LungFX EVLP FDA Approval Means For Shareholders", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-08T04:51:59+00:00", "published_display": "08 Jul 2026 04:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics Corp (UTHR) Stock Up 3.0% but GF Value Says Overvalued -- GF Score: 88/100", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxNM0FTSkpGUHg3LVNHY0RXeTllTEVCeEc2RFRvaDZ3aVN0b2hnS3cwRGJKOFlLMmw4RFFsNnpOSVJHY2k4RmZYUnE3bWhoTU1BX2w1LURlTS13S1N5VUgxZTFmZC1FTzBmQVZmTFZ6TkFxbnFpdEx1cnh6NFFETGNQaFJwUWVFQjRLVWo4M3QzSDFjakNfek9ZR0wzdVZnWEs1bmxrb0VJdWNwMW9QYTVPNU1pcERXWnlnYXA3Z3NsVlpUekhaME9pQ1B0dThIZjlkMFE?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-07T22:33:28+00:00", "published_display": "07 Jul 2026 22:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics CEO Rothblatt sells $5.2m in company stock", "summary": "Martine A. Rothblatt, CEO of United Therapeutics Corp., sold approximately $5.2 million worth of company stock through a pre-arranged trading plan, following an 88% surge in share value over the past year. These sales occurred after she exercised stock options worth about $1.28 m", "url": "https://www.investing.com/news/insider-trading-news/united-therapeutics-ceo-rothblatt-sells-52m-in-company-stock-93CH-4779451", "source_name": "Investing.com", "published_at": "2026-07-07T14:10:16", "published_display": "07 Jul 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RTP drugmaker strikes $300M deal for Massachusetts company", "summary": "United Therapeutics, based in Research Triangle Park, has acquired Massachusetts-based Thymmune for $300 million. This acquisition marks a significant expansion for United Therapeutics into regenerative medicine and organ transplants. The deal was reported by Zac Ezzone of the Tr", "url": "https://www.bizjournals.com/triangle/news/2026/07/06/united-therapeutics-acquires-thymmune.html", "source_name": "The Business Journals", "published_at": "2026-07-06T22:39:13", "published_display": "06 Jul 2026 22:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics Corporation (UTHR) Stock Analysis: A Closer Look at Its 19.67% Potential Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxNZW42dnVCcnE0R2ViTXFsbzFPS0l1VldYb0hnVDY4RWpnSmNmczRONlNEOEVtTXQzTzY2Y1BKMnA2ZFl0VzZjV193S1dwYTJ0OXhoT0RIRERvR3cxemstSEc1Nk5RTXkzcHptVlZmWWtKb3BfVWhkV3BoaUJjbTR2c1ZSdnljb2hkb3A3M3RxaW5ubnNsOGV3cTR5WEdEWXE3aHhCbF9iMFl6anVzYTN6emhZWm5zb1dpN2dGNDE5YjR5Z09hSTJWbkpLSnVnWGpaOTJyRWRZMmc2Wi0zVFdn?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-06T09:21:47+00:00", "published_display": "06 Jul 2026 09:21", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics (UTHR) Following LungFX Approval Is It A Buying Opportunity Or Priced In", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind Stock Plummets After Partner United Therapeutics Unveils New \u2018Category Killer Product\u2019", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7gFBVV95cUxQX2cyYnVaVExIWG1QRjNUMVdkQ1Y2eW5VRzJ2WE13ckJXenVLV3F6ZFR4SEcyR2lsc2pveERra0ZxV3ZUUDZTNndrcXZ3aXFGenRmUkZacnM2THRPaTZ2dXdQR3k5ZDh6Q3dpUEV5cll0cUw3c1o2bTZmX2hvXzJkZEhaeDAxYV9id2hodTlQUUt2VWVtNzdMbzhKSFJTd3JXSVNwVGVRZWYxR0Q3aTJwT2ZrYThYU1ZvV2dIRlgzaXhGSzk5dndObW0wclU5QW9zQW5CeDhqQ0JuSm16Wlk5QlZ6aVdVdW0zNVh5MTJn?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-03T03:21:09+00:00", "published_display": "03 Jul 2026 03:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: United Therapeutics Corporation Acquires Thymmune Therapeutics", "summary": "United Therapeutics Corporation has announced the acquisition of Thymmune Therapeutics. The terms of the acquisition, including the financial details and strategic implications for both companies, are expected to be elaborated upon in the full press release. This move signifies U", "url": "https://www.moomoo.com/news/post/72393890/press-release-united-therapeutics-corporation-acquires-thymmune-therapeutics", "source_name": "Moomoo", "published_at": "2026-07-02T22:39:13", "published_display": "02 Jul 2026 22:39", "sentiment": "positive", "sentiment_pct": 68, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics buys Massachusetts biotech Thymmune Therapeutics for $140M", "summary": "United Therapeutics has acquired Thymmune Therapeutics for $140 million, a move that aligns with United Therapeutics' mission to enhance organ health and transplants. The acquisition occurred shortly after United Therapeutics received FDA premarket approval for a lung transplant ", "url": "https://www.bizjournals.com/washington/news/2026/07/02/united-therapeutics-thymmune-acquisition.html", "source_name": "The Business Journals", "published_at": "2026-07-02T20:11:39", "published_display": "02 Jul 2026 20:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Thymmune Therapeutics acquired by Maryland biotech for $140M", "summary": "Thymmune Therapeutics has been acquired by United Therapeutics for $140 million. This acquisition, which closed on Thursday, integrates Thymmune's thymus cell therapy platform with United Therapeutics' focus on lung disease treatments and pig-to-human transplant research. The dea", "url": "https://www.bizjournals.com/boston/news/2026/07/02/thymmune-acquisition-united-therapeutics.html", "source_name": "The Business Journals", "published_at": "2026-07-02T19:35:39", "published_display": "02 Jul 2026 19:35", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics acquires Thymmune for $140 million", "summary": "United Therapeutics (NASDAQ:UTHR) has acquired Thymmune Therapeutics for $140 million in cash, with potential additional milestone payments of up to $160 million. Thymmune specializes in preclinical regenerative thymic cell therapies for immune-related diseases, including THY-100", "url": "https://grafa.com/en/news/united-states/united-therapeutics-acquires-thymmune-140-million", "source_name": "grafa.com", "published_at": "2026-07-02T14:11:39", "published_display": "02 Jul 2026 14:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics buys Thymmune, adding thymus cell therapy platform", "summary": "United Therapeutics (NASDAQ: UTHR) has acquired Thymmune Therapeutics for $140 million in cash, with potential earn-out payments of up to $160 million. Thymmune specializes in scalable, regenerative thymic cell therapies derived from induced pluripotent stem cells (iPSC), aimed a", "url": "https://www.stocktitan.net/news/UTHR/united-therapeutics-corporation-acquires-thymmune-rcxz36hclcar.html", "source_name": "Stock Titan", "published_at": "2026-07-02T10:11:39", "published_display": "02 Jul 2026 10:11", "sentiment": "positive", "sentiment_pct": 73, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics Corporation acquired Thymmune Therapeutics, Inc. for $300 million.", "summary": "United Therapeutics Corporation (NasdaqGS:UTHR) has acquired Thymmune Therapeutics, Inc. for a total consideration of $300 million. The acquisition includes an upfront payment of $140 million in cash, with an additional potential $160 million in earn-out payments tied to clinical", "url": "https://www.marketscreener.com/news/united-therapeutics-corporation-acquired-thymmune-therapeutics-inc-for-300-million-ce7f5fd3d08cf327", "source_name": "www.marketscreener.com", "published_at": "2026-07-02T08:40:00", "published_display": "02 Jul 2026 08:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics chairperson & CEO Rothblatt sells $5.18m stock By Investing.com", "summary": "Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, sold 9,500 shares of the company\u2019s common stock for approximately $5.18 million. This transaction followed the exercise of stock options and was conducted under a pre-arranged 10b5-1 trading plan. Despite the in", "url": "https://ng.investing.com/news/stock-market-news/united-therapeutics-chairperson--ceo-rothblatt-sells-518m-stock-93CH-2581009", "source_name": "Investing.com Nigeria", "published_at": "2026-07-01T20:11:08", "published_display": "01 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Oliver Patch Project Announces United Therapeutics Corporation Named Visionary/Presenting Sponsor of National Patch Day 2026", "summary": "The Oliver Patch Project has announced that United Therapeutics Corporation will be the Visionary/Presenting Sponsor for National Patch Day 2026. This initiative aims to spread hope and encouragement to children, teens, and young adults nationwide who are facing cancer, serious i", "url": "https://www.prnewswire.com/news-releases/the-oliver-patch-project-announces-united-therapeutics-corporation-named-visionarypresenting-sponsor-of-national-patch-day-2026-302815896.html", "source_name": "PR Newswire", "published_at": "2026-07-01T13:39:19", "published_display": "01 Jul 2026 13:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics Corporation Acquires Thymmune Therapeutics", "summary": "United Therapeutics Corporation has acquired Thymmune Therapeutics for $140 million in cash, plus potential earn-out payments of up to $160 million. Thymmune specializes in scalable, regenerative thymic cell therapies for conditions like post-transplant organ tolerance, immunodef", "url": "https://ir.unither.com/press-releases/2026/07-02-2026-113022825", "source_name": "United Therapeutics Investor Relations", "published_at": "2026-07-01T00:12:07", "published_display": "01 Jul 2026 00:12", "sentiment": "positive", "sentiment_pct": 71, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics Insider Sold Shares Worth $5,167,734, According to a Recent SEC Filing", "summary": "An insider at United Therapeutics Corporation recently sold shares totaling $5,167,734, as disclosed in a recent SEC filing. The article, however, is reserved for members only, requiring registration to access the full details of the transaction. United Therapeutics develops and ", "url": "https://www.marketscreener.com/news/united-therapeutics-insider-sold-shares-worth-5-167-734-according-to-a-recent-sec-filing-ce7f5fdfdd80f627", "source_name": "www.marketscreener.com", "published_at": "2026-06-30T19:39:19", "published_display": "30 Jun 2026 19:39", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Approves United Therapeutics\u2019 LungFX For Centralized Lung Perfusion, On A Narrow Indication", "summary": "The FDA has approved United Therapeutics' LungFX for centralized lung perfusion. The approval is specifically for a narrow indication, highlighting the targeted application of this medical device. This development is significant for the field of respiratory medicine.", "url": "https://insights.citeline.com/medtech-insight/policy-and-regulation/approvals/fda-approves-united-therapeutics-lungfx-for-centralized-lung-perfusion-on-a-narrow-indication-XXUEG4MZGJCR7PJGIEBHR3BPXM/", "source_name": "Medtech Insight", "published_at": "2026-06-30T13:09:45", "published_display": "30 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 76, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA approves United Therapeutics' LungFX to assess donor lungs", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNVVdaX0MtdEFZODVmaXU5UDVLR0pOeFBiaFVnWmtQeWg3WF9MRE1SemVqNkppTVBIYmlhem83VHA3dUQxMWY5VmpCN0EtRnhvS0YyZUtxeS1EdVNKVE4xYzdFY204XzlITnBzdTg4V2o5eVkxSlk0b2RIckpybnNkYWllVk4xbkpJd0d4SzdyejhUZ1JjRDZOd1NLM2Z0RXF6WmlycENyME5MclU0WWdlWjlzWXFHLVM3MjNTSkJB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics | UTHR Stock Price, Company Overview & News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiY0FVX3lxTFBnckpMRjBiNmc0aHZwc2ZxS1VoNUdPSGdiUjRiQl9VTEt3RWNlNTVXLVVuU0lCMDJHNEYwSEt2TG52VWJDMWxYbklPbFRJUHhjcUVHVHVRWU5iaXRLRHA5Ukt4cw?oc=5", "source_name": "Forbes", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics EVP Mahon sells $4.5m in company stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNekFJWUNvUVhZQS1kSXFWM0M2cDVUdFU3SkNGSlNRQ3VlWVlSc1VacGJUcXJLLVNSckNVaTI5Z0lKSnVLS1BjMnh6UWx3dUtLY2lwd1dXSHpyX2pBendCUWp0bDRZYlloRFFnaU1Pa3lJSkY1NkY0c0NhWjRZam5kMzRUckwzQmJ3bTBoRlN1bVZuS25qRU5uNHN4Umw5VXY0eC0tSDVOakJsbFZ4Q2FLeWV2YkNhMVdPMG80UjJ3?oc=5", "source_name": "Investing.com", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At United Therapeutics (UTHR) Valuation After Strong Long Term Shareholder Returns", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQRWEzdmN3d05USF9aelk3eHV6SHAwTTVzZVdiRUhZTmJjbWNGVk9OSl9QTnotd2pfT3RxZktfZVVHaFU0Q3htZjFScjRrdS1NdXNFYVk5NWYyZjkwZ0ZpM25YZnJ3R2pWbUctT3pjUUdwbEM3bFhmbWR1UldvWEpnanlmVEl4U1JQbHA0LXZya2VkZHdJUDRMdVIwcW42QTM3RlFxSXYyMA?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is United Therapeutics (UTHR) Down 3.8% Since Last Earnings Report?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQbUtpbjhyZm9DWjNrLVFrQXJSLW9UdHVHaWxSSmtSSWxDZGtfUHlnRVFSOXJIY2U4aEZDQlhUS29TZGZBZFZ3TmR0OURrV281OFh1ZWhxeHd4OTIzZ0pMYXVKRld6bV84NVRYQlRCZUFzZ3ZKd0dqVTdpX0pIRVVYckEyeEx6WUpQRmVuaEV5SUttZmRUMDVNTlYtamwwVE0?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Story Around United Therapeutics (UTHR) Is Shifting On Trials Pricing And Valuation", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQU2tGREs5ZzZNNWxmQ3VpME1rZmFWYVB6N01ENlVVelNSamFwcThZRVJZQVF6dXpVQWE5V2lBeGQxMGkxQ2EtVlg2YldkTWV4RjM3M1o0UGFTU3VmM19SakUteFZHUHdNVUxKM2RCYkIwNTNndVBWTnc5QUh2UnFuNnd1eUUtc3pDVWt5OUhIMlFyM09BOVBnZjhta0lJYW9QSW5QVQ?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics (UTHR): Company Profile, Stock Price, News, Rankings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTFBrNTlRY05sd1JFMlMxeTNmMzhvODN0XzRVVHlEUXJyUDZRWF8tRnhUQi1xdHVYYndZR0FfLWVoLXlZXzB0RngzNkk0MUpGNzhTNkd0V0NIRXFiQThR?oc=5", "source_name": "Fortune", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Insider Has Just Sold Shares In United Therapeutics", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics chairperson & CEO Rothblatt sells $5.5m in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOMmdaSXNiSlZ0ZDIwWEl6aE9mdE5xQ3JZd2l0RFo1VXhVeDlLVnYxdzFHak9MUnpOcFNGRkc0WE96VHBrQ1hzeWpaYTFqNlpIQzdxRUVqa3RoVmRBbV9tU0RTOWJia1BsMjRmYmJGSFo5NVMyaDlPS0xaTWNKcEQwbmdueTQ4NDhPeFQ4M0RxZVVNS2dnNUZpWWtSU19UbkFtbFJzcE5ueEV6MU1ORzBPZ25aYjVrcUI1XzQtZjVTM3JVbGVxX2hESGpR?oc=5", "source_name": "Investing.com", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider United Therapeutics (UTHR) After Its 94% One Year Surge?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind stock surges on United Therapeutics partnership deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQWEdUSkFDa3RRbWZYc3ZTelJ5dk8yYVhkM0ZSV0VQNnhheWsyVEl5eS1SUDhzMXg5dlAxZVJPLUk4Z0c2WDlRdnFON2hkM19rSTl3OTJKczFhb2Q1WVpIS21Pb0gxVk1PVUZaZXNSODkxT2cxeDEzTGZxN09YcXhXWE13VGtWdFppbk5UcjNCUlZxYktFUThCV3lVNlliN1M0X3hOX3NFbjNVVW1rZVZXbmFSWW9ETVJ4c3hRNk5sVDI?oc=5", "source_name": "Investing.com", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United Therapeutics (NASDAQ:UTHR) Reports Sales Below Analyst Estimates In Q1 CY2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxPMHZzemJjSl95blhMbTRZTVg1ZkxzQWFzRG5QcTNVOE9uMTVOY01MRVFRNEppank2V1YtNzZ1RVhIT2E5VUw1blJ1RHl1QnAtUGJ5VFdJNWtGWjJ0cTFLbk1vaWZ6TXFsNkJLWlRDUWplWkppSUhRTDlZOHlIeDBITzZaWjhEckpVRVBQdUlVVlhrLXRXcGxMOFB3WTNaSkVPNHZHckhUVjlHOWVMVUtKQXVkdDRHOExUZjgtSTFUOTdiOVN5TDhwY1dPbzM3dzJPOHdNWm1nZGhFNlBGNDMxbUYwbw?oc=5", "source_name": "StockStory", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "3 Reasons Investors Love United Therapeutics (UTHR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPQjdnZWhXQzBjYWZyNXpWRFBYUDlzdFZBZnIxZ0M0eVVCQjBrcWpCeHcyd0JsbC1Dazg0XzZIT0drZWdEQkwxM05BdGlhTUdxOVcwRkpUZmZJNXZtaGZuQkVsTThOZTFPTmFhMU9DVExEeF9ETmZLX1dGQ1ZTdVA1UW5vbm5Yd3NSQUNJV0x3bXcwcW5qTHREckczQmFzS214NF85VlBMWWJFYmtTcmdORGF5VQ?oc=5", "source_name": "StockStory", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider United Therapeutics (UTHR) After Its 92% One Year Surge?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPTl91YVNfU2Rzbk9fUGl0c1A5ZXVDNjRxdFRvSG5iM2hnUUVhc1lRREEzVmdWdUtKWXByWDJ4VDROY1ZvVUhnTkdQUGVKSDZoWktFTXJqTmZVeDNxSkFBa0VCVlQ4YzU4NUpFRGhGdEZSTFBZYU5EVEI3SDhxRzBib2JaOWd0a2ViWVdYTF9JQ2otMEw5Mlg3UzJvNWswYUQ1N3FhdQ?oc=5", "source_name": "Market source", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 94, "total_relevant": 65, "sentiment_summary": {"positive": 25, "negative": 3, "neutral": 37, "score": 57, "total": 65, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 83, "events": [{"event": "general", "label": "Market update", "weight": 23.65, "count": 43}, {"event": "earnings", "label": "Earnings", "weight": 3.3, "count": 6}, {"event": "deals", "label": "Deals and strategy", "weight": 3.3, "count": 6}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 2.75, "count": 5}, {"event": "liquidity", "label": "Balance sheet", "weight": 2.2, "count": 4}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}], "positive_events": 25, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 547.06, "latest_week": "2026-07-10", "one_week_move": -1.6, "four_week_move": 0.2, "twelve_week_move": -7.0, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": -0.832486, "market_dynamics_buy_signal": false, "relative_strength": -0.271427, "fair_value_gap": 56.2, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 54.5911, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-1.6% over one week, +0.2% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 67, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Investing.com Canada", "count": 7}, {"label": "Market source", "count": 7}, {"label": "Investing.com", "count": 6}, {"label": "Moomoo", "count": 4}, {"label": "MT Newswires", "count": 4}, {"label": "Quartr", "count": 4}, {"label": "simplywall.st", "count": 4}, {"label": "Stock Titan", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 65}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 43}, {"label": "Earnings", "count": 6}, {"label": "Deals and strategy", "count": 6}, {"label": "Regulatory and legal", "count": 5}, {"label": "Balance sheet", "count": 4}, {"label": "Analyst action", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "83/100 classification confidence."}, {"label": "Company focus", "value": "65", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-1.6% over one week, +0.2% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Is United Therapeutics a \"Quant King\" Favorite for a Reason"}], "updated_at": "2026-07-16T08:06:31.851239+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}